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A fast and reproducible microwave-driven process has 
allowed us to synthesise Neridronate-functionalised 
nanoparticles. Contrary to traditionally the phosphate groups 
decorate the outside layer of the particles providing Ca2+ 
binding properties in vitro and selective accumulation in vivo 
in the atheroma plaque. In vivo and ex vivo detection by T2-
weighted MRI is demonstrated and validated by histology. 
The accumulation in the plaque takes place in less than one 
hour since the intravenous injection, which is particularly 
suitable for clinical applications. 
The use of iron oxide nanoparticles (IONP) in biomedicine is a well-
established and vast field encompassing from drug-delivery to 
hyperthermia and clinical diagnosis of several diseases.1,2 Lately 
there has been an increasing deal of attention to the use of 
microwaves synthesis (MWS) for the production of high quality 
nanoparticles of different composition. MWS dramatically reduces 
reaction times, increase yields and enhances reproducibility, 
parameters of critical importance for the synthesis of IONPs.3–5 MW 
technology allows for a fine-tuning of the main parameters affecting 
the behaviour of IONPs. This way ultrasmall nanoparticles (<10 nm) 
or larger ones (20-100 nm) can be easily obtained.5–8 This flexibility 
is also clear in the synthetic methodologies than can be used, from 
coprecipitation to thermal decomposition, as we demonstrate 
here.9,10 Bisphosphonates (BiP) are chemically stable derivatives of 
inorganic pyrophosphate (PPi) and have been used in the clinical 
practice for more than three decades.11 Bisphosphonates are used to 
treat a wide variety of conditions because of, like their natural 
analogue PPi, their high affinity for bone mineral, binding to 
hydroxyapatite crystals.11 BiP molecules have been previously used 
for their binding properties towards the Fe3O4 surface.12–14 Here we 
propose a radically different approach; to decorate the outer layer of 
the particle rather than attach to the surface to keep the calcium 
binding properties of these functionalities and target the 
atherosclerosis plaque. Neridronate (Scheme 1) is a BiP with five 
methylene units and a final free amino group, particularly well suited 
for the functionalisation of the carboxylic groups on the surface of 
the nanoparticles. 
Scheme 1. Synthesis of neridronate functionalised nanoparticles (3). 
Reagents and conditions: (i) 60 ºC, 2 min.; (ii) 180 ºC, 20 min.; (iii) KMnO4, 
BTACl, 105 ºC, 300 W, 9 min.; (iv) pH 2.9, 105 ºC, 300 W, 9 min.; (v) EDC, 
sulfo-NHS, pH 7.0, 30 min.; (vi) HEPES pH 7.7, 2 h.  
Atherosclerosis is an inflammatory pathology of the blood vessel 
wall in which plaque builds up inside the arteries. Plaque is mainly 
made up of lipids, cholesterol, calcium, macrophages and several 
substances found in the blood. Over time, plaque hardens and 
narrows the arteries, limiting the flow of oxygen-rich blood to the 
organs. The acknowledgment of the importance of this pathology 
from a global health and economical point of view has motivated a 
great deal of research for the early diagnosis of the plaque by non-
invasive techniques.15,16 The specific targeting of the plaque can be 
addressed with several biomarkers like metalloproteinases, LDL-
oxidised, calcium vesicles, receptors involved in neoangiogenesis or 
macrophages.17–19 The aim of this work was to use MWS for the 
production of high-quality biocompatible nanoparticles and to 
functionalise them with neridronate. Our hypothesis was that the 
Ca2+ binding properties of this group would provide in vivo targeting 
towards the calcium vesicles in the atheroma plaque and therefore be 
of use for an easy diagnosis of atherosclerosis plaque.  
Oleic acid–coated iron oxide nanoparticles (OA-IONP) were 
synthesised in the microwave by a modification of published 
protocols.20 Briefly, a mixture containing Fe(acac)3, oleic acid, 
oleylamine and 1,2-dodecanediol in benzyl alcohol was stirred at 
60ºC for 2 min at 300 W. After that, the temperature was increased 
from 60ºC to 180ºC and stirred during 20 min (Scheme 1). As 
typically occurs when using MWS (Discover SP, CEM), due to the 
very fast heating, the NPs can be synthesised with very small size. 
The core size, by Transmission Electron Microscopy (TEM), for the 
very homogeneous hydrophobic nanoparticles (1) is 3.7 ± 0.8 nm 
(N=50, Figure 1a). Besides high resolution TEM shows the lattice 
fringes on the Fe3O4 cores, demonstrating excellent crystallinity 
(Figure 1a). The hydrodynamic size, by Dynamic Light Scattering 
(DLS), is also extremely small with a value of 7.5 nm (Figure 1c). 
The infrared spectrum of the nanoparticles (Figure S1) shows the 
typical bands for OA-IONP.21 To render these hydrophobic 
nanoparticles stable in water we chose a direct chemical 
modification of the surfactant with the help of microwave 
technology.21–23 The use of MWS in this modification (Scheme 1) 
clearly demonstrates the most important advantage of this 
technology, the rapidness and reproducibility of the reaction. The 
process was divided in two steps of 9 minutes each, first for the 
formation of the complexes between MnO4- and the olefin and the 
second step for the cleavage of the oleic acid molecule. The 
synthesis rendered Azelaic acid-IONP (2) with a hydrodynamic size 
of 30 ± 5 nm by DLS (Figure 1c), similar to the value obtained by 
the thermal approach.	   The excellent reproducibility achievable by 
MWS with our equipment (Discover SP, CEM) is also shown in 
Figure 1d. It can be seen how after four repetitions of the synthesis 
the same size and size distribution was obtained. The value for the 
zeta potential (-44 mV) at pH 7 is also in the expected range. TEM 
images of nanoparticles 2 show that there is no aggregation upon 
modification of the oleic acid structure. The core size for the 
hydrophilic nanoparticles is similar to particles 1, with a value of 4.9 
± 0.9 nm (N=50, Figure S2). FTIR spectrum of nanoparticles 2 
shows the expected changes due to the breaking of oleic acid chain 
(Figure S1). There are three modifications in comparison with 
spectrum for 1; the lack of the C-H signals due to the minor number 
of CH2 groups at 2854 cm-1 and 2925 cm-1, the broadened C=O peak 
at 1660 cm-1 due to the presence of two carbonyls in the molecule 
and the disappearance of the signal at 1432 cm-1 assigned to double 
bond in oleic acid. On the other hand, in the spectra of 2, at least 
three bands can be clearly assigned to the azelaic acid molecule at 
1000 cm-1, 1045 cm-1 and 1175 cm-1. Relaxivity values for 
nanoparticles 2 were also measured to determine their performance 
as T2-weighted MRI contrast agents. Relaxivity values were 15.3 ± 
1.1 mM-1s-1 for r1 and 90.7 ± 3.5 mM-1s-1 for r2. These values are 
similar to the previously reported for the thermal synthesis. Only a 
slightly larger r1 value that can be attributed to the much faster 
synthesis in MW and therefore smaller cores in the nanoparticle. 
Once nanoparticles 2 were obtained we carried out the final 
modification by the amide formation between the amine group in 
neridronate and the carboxylic groups in azelaic acid molecule. For 
this, traditional EDC/sulfo-NHS conjugation was used, since 
employing an activated carboxylate with the sulfo-NHS ensures 
colloidal stability during the reaction. Final magnetic purification 
rendered nanoparticles 3 with very good colloidal stability. The 
TEM images for the neridronate-functionalised nanoparticles are 
shown in figure 1b. It is clear the homogeneous distribution, the lack 
of aggregation and the crystallinity of the sample, with size of the 
core of 5.5 ± 0.7 nm (N=50, Figure 1b). Regarding hydrodynamic 
size they show an almost identical value than 2 of 40 ± 4 nm and a 
narrow size distribution, confirming that the whole process did not 
change the core of the nanoparticle and only a slightly larger 
hydrodynamic size is obtain as expected (Figure 1c). The 
incorporation of the new functional group was confirmed both by 
FTIR and Energy-dispersive X-ray spectroscopy (EDX) (FigureS1 
and Figures S3). Infrared data show the expected changes, like a 
slight reduction in the wavenumber of the carbonyl band, from 1660 
cm-1 to 1636 cm-1, due to the formation of amide bonds and the 
presence of bands that also appear in neridronate spectrum, like 
those at 1179 cm-1 and 1043 cm-1. EDX also confirms the presence 
of neridronate in the nanoparticle with 10.5% atomic weight of 
phosphorous relative to iron (Figure S3). Relaxivity values for 
nanoparticles 3 were also similar to those for 2, 11.2 ± 1.7 mM-1s-1 
for r1 and 93.3 ± 3.1 mM-1s-1 for r2. At this point we checked the 
Ca2+ binding properties of the nanoparticles due to the presence of 
the bisphosphonate groups. It has been previously shown that the 
modification in the aggregation state of the nanoparticles can be 
detected by changes in the relaxation time values.24 For that a 50 µg 
Fe/mL solution of nanoparticles 3 was prepared and titrated with 
different calcium solutions (blank, 12 µM, 25 µM and 50 µM).  
Figure 1. a) TEM images, at two magnifications, for 1; b) TEM images, at 
two magnifications, for 3; c) Hydrodynamic size for nanoparticles 1, 2 and 3; 
d) Hydrodynamic size for 2 in four different synthesis; e) Evolution of T2
relaxation time in a solution of 3 as a function of time and calcium 
concentration and f) Cell viability after incubation with 3 at different 
concentrations and incubation time. 
As figure 1e shows the value of the T2 relaxation time increments 
linearly with the amount of Ca2+ and the time of incubation due to 
the formation of clusters of nanoparticles (nanoparticles in the same 
solution but without Ca2+ remained stable). These results confirm 
that the binding capacity of the bisphosphonate groups in 3 is not 
lost during the functionalisation step, as was indeed expected. This is 
a fundamental result since our hypothesis is that the calcium binding 
capacity would enable the plaque targeting capabilities through 
macrophage capture.25 Cellular uptake by Mouse Adult Fibroblasts 
(MAFs) C57/BL6 of nanoparticles 3 was assessed by flow 
cytometry, by an increased side scatter (SSC) and by bright field 
microscopy after using Perls staining in cell culture (Figure S5).26 
SSC is increased after treatment with successively higher doses of 3 
as expected with the incorporation of the nanoparticles. Increased 
SSC was observed in a dose dependent manner. Cell size and 
morphology after incubation for 24 hour, as well as the cell uptake 
were assessed by Perls staining confirming the incorporation of 3 in 
the cells. Cytotoxicity of the 3 was also checked with MAFs, cell 
viability and proliferation were studied for three concentrations and 
three incubation times. Results are shown in Figure 1f and Figure S4 
and clearly shown that there is no remarkable cytotoxicity even at 
such a high concentration as 100 µg/mL. For the in vivo MRI study 
ApoE-/- mice, 48 weeks old, were used. First, aorta and carotids basal 
images were taken (Figure 2a), where the formation of the 
atherosclerotic lesion can be clearly seen. After that, a solution of 
neridondronate-functionalised nanoparticles (3, 100 µL, 1 mg 
Fe/mL) was intravenously injected in mice and images were 
recorded one hour post injection. Figure 2a shows the plaque in the 
aorta pre (top) a 1h post injection (bottom). It is clear in these images 
that the plaque, after the injection of the particles, is hipointense in 
comparison to the basal images. This difference in intensity can in 
fact be quantified (Figure 2b) by the selection of two ROIs (region of 
interest) in the plaque and two in the muscle for reference. The 
plaque to muscle relative signal clearly shows a significative 
reduction in the intensity one hour after the injection of nanoparticles 
3. To confirm that this signal reduction was due to the accumulation
of nanoparticles and not because of their circulation in the blood 
their circulation lifetime was studied. Ideally, a good contrast-
enhanced nanoparticle system should accumulate rapid and 
specifically in the targeted area and should be cleared immediately to 
avoid background signal. Besides this accumulation should be as fast 
as possible since this would determine a higher translational 
power.25,27 Nanoparticles 3 were injected (100 µL, 1 mg Fe/mL) and 
the signal in the liver monitored with time. It is clear in the graph 
that after 20 minutes the nanoparticles have cleared from circulation, 
ruling out any possible effect on the images (Figure 2c). To confirm 
these data, ex vivo imaging and histology were performed on the 
studied mice. 
Figure 2. a) in vivo MRI of ApoE-/- mouse previous (left) and one hour after the i.v injection of 3 (right); b) Plaque to muscle relative signal intensity previous 
(basal) and one hour after the i.v injection of 3; c) Liver to muscle relative signal intensity at different time points after the injection of 3; d) ex vivo images of 
the aorta for two mice, without the injection of nanoparticles (left) and one hour after the injection of 3 (right) and e) histology of plaque sections stained with 
von Kossa and prussian blue, scale bar is 22.2 µm. 
Mice, with and without nanoparticles, were sacrificed and their 
aortas extracted to carry out ex vivo MRI. Figure 2d shows the 
images of the basal and 1 hour post injection where a clear 
hipointense signal is observed in agreement with in vivo data. Finally 
we carried out histology of the different mice looking for the 
colocalisation of nanoparticles 3, macrophages and calcium deposits 
(Figure 2e, Figure S6 and Figure S7). Three different stainings were 
used, von Kossa for calcium deposits, F480 for macrophages and 
Prussian blue for iron. Images clearly show how the iron deposits 
colocalise with the presence of Ca2+ and, only in these spots, with 
macrophages. In the different images it is clear that the 
colocalisation of iron with macrophages only occurs when also 
calcium is present (See Figures S6 and S7). Confirming our 
hypothesis of plaque accumulation triggered by the calcium binding 
properties of neridronate-functionalised nanoparticles. 
Conclusions 
We have demonstrated a new approach on the combined use of 
bisphosphonates and iron oxide nanoparticles. By microwave 
technology we synthesised neridronate-functionalised, after a 
full characterisation we showed their rapid accumulation in 
vivo, when most of the iron oxide nanoparticles for plaque are 
visualized at least 24 hour after the injection. Thus, the high 
affinity due to the functional group and specific interaction with 
	  	  
calcium and posterior macrophage uptake of the agglomerates, 
make our proposal very attractive for translational applications.  
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